Greenwich LifeSciences, Inc. (GLSI) Insider Trading Activity

NASDAQ$16.38+0.46 (2.89%)
Market Cap
$233.68M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
163 of 849
Rank in Industry
96 of 491

Largest Insider Buys in Sector

$350M
$217M
$172M
$109M
$107M
$104M

GLSI Insider Trading Activity

GLSI Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$565,030
12
100
Sells
$0
0
0

Related Transactions

Patel SnehalCEO and CFO
12
$565,030
0
$0
$565,030

About Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, …

Insider Activity of Greenwich LifeSciences, Inc.

Over the last 12 months, insiders at Greenwich LifeSciences, Inc. have bought $565,030 and sold $0 worth of Greenwich LifeSciences, Inc. stock.

On average, over the past 5 years, insiders at Greenwich LifeSciences, Inc. have bought $1.32M and sold $0 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Patel Snehal (CEO and CFO) — $565,030.

The last purchase of 700 shares for transaction amount of $9,170 was made by Patel Snehal (CEO and CFO) on 2026‑07‑29.

List of Insider Buy and Sell Transactions, Greenwich LifeSciences, Inc.

2026-07-29PurchasePatel SnehalCEO and CFO
700
0.0049%
$13.10
$9,170
+26.29%
2026-07-28PurchasePatel SnehalCEO and CFO
1,500
0.0103%
$13.59
$20,385
+19.63%
2026-07-27PurchasePatel SnehalCEO and CFO
1,500
0.0104%
$13.62
$20,430
+19.57%
2026-07-24PurchasePatel SnehalCEO and CFO
1,100
0.0074%
$12.88
$14,168
+23.65%
2026-07-23PurchasePatel SnehalCEO and CFO
2,500
0.017%
$13.14
$32,850
+21.61%
2026-01-13PurchasePatel SnehalCEO and CFO
1,800
0.0134%
$29.83
$53,694
-23.05%
2026-01-12PurchasePatel SnehalCEO and CFO
2,900
0.0215%
$27.54
$79,866
-16.44%
2025-12-31PurchasePatel SnehalCEO and CFO
4,300
0.0303%
$21.36
$91,848
+6.66%
2025-12-30PurchasePatel SnehalCEO and CFO
2,900
0.0208%
$21.73
$63,017
+2.05%
2025-12-18PurchasePatel SnehalCEO and CFO
4,100
0.0302%
$12.62
$51,742
+79.98%
2025-11-25PurchasePatel SnehalCEO and CFO
4,600
0.0341%
$8.37
$38,502
+157.74%
2025-11-07PurchasePatel SnehalCEO and CFO
10,600
0.0712%
$8.43
$89,358
+142.61%
2025-10-31PurchasePatel SnehalCEO and CFO
2,300
0.0169%
$9.26
$21,298
+123.78%
2025-04-25PurchasePatel SnehalCEO and CFO
3,600
0.0271%
$9.88
$35,568
+12.93%
2025-04-17PurchasePatel SnehalCEO and CFO
5,400
0.0385%
$8.98
$48,492
+25.20%
2025-04-07PurchasePatel SnehalCEO and CFO
3,600
0.026%
$9.10
$32,760
+14.60%
2025-04-04PurchasePatel SnehalCEO and CFO
5,500
0.0414%
$8.73
$48,015
+24.24%
2025-01-10PurchasePatel SnehalCEO and CFO
2,500
0.0191%
$12.51
$31,275
-13.41%
2025-01-07PurchasePatel SnehalCEO and CFO
1,800
0.0138%
$13.75
$24,750
-22.38%
2025-01-06PurchasePatel SnehalCEO and CFO
1,100
0.0084%
$13.31
$14,641
-18.23%
Total: 118
*Gray background shows transactions not older than one year

Insider Historical Profitability

<0.0001%
Patel SnehalCEO and CFO
5611402
38.2295%
$89.33M840
+2.27%
McWilliams Daviddirector
620301
4.226%
$9.88M30
<0.0001%
Hallock Kennethdirector
397304
2.7068%
$6.33M40
<0.0001%
Rothe Ericdirector
313226
2.134%
$4.99M10
Thompson JayeVP Clinical Reg Affairs
264148
1.7996%
$4.21M210
<0.0001%
Daugherty Frank JosephChief Medical Officer
90121
0.614%
$1.43M50
<0.0001%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$22,710,871
107
8.53%
$220.62M
Greenwich LifeSciences, Inc.
(GLSI)
$6,146,922
96
-4.70%
$233.68M
$19,239,249
50
-2.24%
$238.33M
$168,352,523
35
13.58%
$218.79M
$3,668,031
23
2.05%
$243.03M

GLSI Institutional Investors: Active Positions

Increased Positions23+38.33%243,887+20.09%
Decreased Positions25-41.67%131,031-10.79%
New Positions7New164,979New
Sold Out Positions8Sold Out86,224Sold Out
Total Postitions58-3.33%1M+9.29%

GLSI Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Blackrock, Inc.$7,073.002.6%363,299-3,882-1.06%2025-09-30
Vanguard Group Inc$5,494.002.02%282,181+13,179+4.9%2025-09-30
Geode Capital Management, Llc$2,767.001.02%142,116+3,134+2.25%2025-09-30
State Street Corp$1,595.000.59%81,946-301-0.37%2025-09-30
Northern Trust Corp$1,478.000.54%75,905-6,874-8.3%2025-09-30
Renaissance Technologies Llc$748.000.27%38,400+11,100+40.66%2025-09-30
Marshall Wace, Llp$624.000.23%32,051-24,091-42.91%2025-09-30
Deutsche Bank Ag$419.000.15%21,502+21,502New2025-09-30
Citadel Advisors Llc$408.000.15%20,942+7,174+52.11%2025-09-30
Strs Ohio$389.000.14%20,00000%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Company
About Prismo.proIdeasArticlesPrivacy PolicyTerms of ServiceContact Us
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksStock NewsInsider RatioList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.